C. L. Benhamou

Learn More
Postmenopausal women with osteoporosis received 75 mg risedronate on two consecutive days each month or 5 mg daily for 12 months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule. Patients perceive less frequent(More)
This study evaluates the effect of hydrolyzed collagen (HC) on bone health of ovariectomized mice (OVX) at different ages. Twenty-six weeks after the OVX procedure, HC ingestion was still able to improve significantly bone mineral density (BMD) and some femur biomechanical parameters. Moreover, HC ingestion for 1 month before surgery prevented BMD decrease.(More)
Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient(More)
The authors report five cases of costo-vertebral (CV) joint arthropathies, without osteo-arthritis. The patients had referred pain, with misleading irradiations to the loin or to the abdomen, so that the diagnosis was difficult. The authors have performed in these five cases an arthrography of T11 and T12CV joints. In every case, the arthrography triggered(More)
This paper briefly summarises the most recent developments in multiscale modelling technology as applied to the generation of personalised multiscale models of the musculoskeletal system to be used for the prediction of the risk of bone fracture. We describe how the VHPOP European consortium is compositing all these groundbreaking methods into a radically(More)
The efficacy and safety of weekly oral odanacatib (ODN) 50 mg for up to 8 years were assessed in postmenopausal women with low bone mineral density (BMD). Treatment with ODN for up to 8 years resulted in continued or maintained increases in BMD at multiple sites and was well tolerated. ODN is a selective inhibitor of cathepsin K. In a 2-year phase 2b study(More)
This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing options and provides an alternative for patients who prefer once-a-month dosing. Risedronate is effective in the treatment(More)
Paradoxically, cortical bone has long been less extensively studied than trabecular bone. However cortical bone represents 85% in mass of the whole skeleton, and this constitutes the 1st paradox [1]. Furthermore, it explains also 70% to 85% of the bone strength according to the long bone that we envisage [2]. The vertebrae have long been considered as(More)
The authors report a case of spine involvement in a severe case of rheumatoid arthritis treated with corticosteroids. First, the patient developed acute back pain, related to costovertebral joints arthritis at levels T9–T10. Then, neck pain and cord involvement yielded to diagnosis of cervical interapophyseal joints arthritis; there was a C5–C6 subluxation(More)